Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer and diabetes. These therapies can offer significant benefits in efficacy for specific patient groups and have become more convenient to administer compared to conventional medicines. However, their high costs have limited accessibility for many patients globally. Biosimilar versions of biologic medicines are now helping to change this landscape by providing more affordable treatment options. These products offer equally effective, safe and cost saving alternatives, which can expand access to essential biologic therapies.
Despite the demonstrated benefits and their potential, several challenges remain in the broader adoption of biosimilars. Regulatory barriers, lack of awareness and literacy among healthcare professionals, and limited manufacturing capabilities in certain regions can hinder the widespread acceptance and utilisation of biosimilars. Addressing these challenges requires coordinated efforts among governments, healthcare providers, and the pharmaceutical industry to promote education and streamline regulatory processes.
Based on country experiences, the webinar will offer an opportunity to discuss policies to promote the use of quality-assured biosimilar - registration pathway and capacity, public procurement agencies choices around biosimilars, their availability in the public versus private sectors, particular products with access issues.